Latest News

LATITUDE Atlas saw more than 35% of patients receiving zasocitinib 30 mg once daily reaching a PASI100 response at week 16, the primary endpoint.

This SDPA Summer 2026 talk highlights off-label treatment tips for dermatology clinicians in conditions such as alopecia areata, morphea, and different genital conditions.

This episode covers recently released data regarding the Dexcom G7 and Eli Lilly’s investigational triple agonist retatrutide from ADA 2026.

This preview of the 2026 SDPA Summer Dermatology Conference highlights different sessions and interviews covered by the HCPLive team.

An APP forum discusses navigating a complex biologic landscape with significant administrative, access, and patient education responsibilities that physicians may encounter less directly.

Amit Gupta, MBBS, DNB, joins the show to discuss diabetes treatment in a traditionally underserved population and to address the IDF’s work in moving it forward.

Eli Lilly announced FDA approval of a 250 mg every-8-week lebrikizumab maintenance regimen, supported by 32-week ADjoin extension data.

Sparrow Pharmaceuticals presented phase 2a data for the HSD-1 inhibitor clofutriben at ADA 2026.

The FDA marked bemotrizinol as first new active ingredient on the over-the-counter (OTC) sunscreen monograph since the 1990s.

Elecoglipron 75 mg produced 10.5% body weight reduction at 26 weeks in VISTA and a 1.9% HbA1c reduction at 26 weeks in SOLSTICE.

At ATS 2026, Robert Wallis, MD, discussed PanTB-HM findings on FEV1 recovery and NAC antimicrobial interactions.

Ketan Dhatariya, MD, PhD, MS, joins the show to discuss how therapies for diabetes have evolved in the UK in comparison to the US.

twiist improved time in range by 16 percentage points and reduced HbA1c by 0.7 points over 13 weeks in insulin-treated adults with type 2 diabetes, with no severe hypoglycemia events.

This Q&A interview highlights key takeaways regarding hidradenitis suppurativa, raising awareness for HS Awareness week, and the current treatment landscape.

In the phase 2 SLIMMER-UP-SWITCH trial, ecnoglutide delivered greater weight loss and waist circumference reduction than semaglutide at 20 weeks in adults with obesity in China.

Trang Ly, PhD, MBBS, joins the show to discuss Insulet’s recent advancements in automated insulin delivery and the trajectory of the Omnipod platform.

DKA remains a growing challenge in diabetes care, with new data highlighting missed diagnoses, rising admissions, and higher costs.

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

Across a trio of phase 3 trials, CagriSema delivered superior HbA1c reduction and weight loss versus semaglutide in adults with type 2 diabetes

Orforglipron added to titrated insulin glargine reduced HbA1c by up to 2.05% and body weight by up to 6.1% versus placebo, without increasing hypoglycemia risk.

In a post-hoc analysis of ATTAIN-1 and ATTAIN-2, the highest dose of orforglipron delivered meaningful weight loss across all menopause stages.

May 2026 spotlights the ATS 2026 conference and the ALA's State of the Air report.